Shanghai CP Guojian Pharmaceutical Co., Ltd

Company Description

Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a bio-pharmaceutical high-tech company which is co-invested by the CITIC Group and Shanghai Lansheng Guojian Pharmaceutical Co., Ltd. Shanghai CP Guojian Pharmaceutical Co., Ltd focus on the R&D, pilot test and industrialization of antibody drugs. It has become a leader in the domestic antibody class of bio-pharmaceutical companies through long-term efforts, and providing targeted drugs covering major disease fields of Oncology, Transplantation, Autoimmune Systemic Diseases & etc.; its application effects have gained widespread recognition by physicians and patients. As one of the top-level companies, focusing on R&D, manufacturing and distribution of hunman monoclonal antibody drugs, Shanghai CP Guojian Pharmaceutical Co., Ltd has successfully built a leading domestic platform for the development of Antibody Drugs and their industrialization production, grasped sophisticated core technologies and now possesses the innovation ability to continuously develop new drugs. There are currently more than 10 new Antibody Drugs under development, clinical trials or sales, which has filled a crucial void in the domestic biomedical field, and its R&D strength and production capacity have reached international advanced levels. As metioned in the website, CPGJ has established 4 manufacturing lines of 750-litre animal cell culture bioreactors and two full production lines of two 3000L cell culture bioreactors. They are equipped with the largest and the most advanced dimensional purified apparatus in China, which enable CPGJ to manufacture 2 million lyophilized sterile powder vials and 1 million liquid filling vials per year. Now, six 5000-liter lines follow the European Union's strict standards are under construction. By the way, the production line has tot the GMP certificates approved by the authoriteis of China, Brazil, Mexico, colombia, Idian, and Pakistan, and the products has exported to many countries and areas of the world.

Company Information

  • Contact Person:Mr. Bingkun Si
  • Department:Manager
  • Telephone:
  • Fax:
  • Zip:201203
  • Business Type:Manufacturing
  • Year Established:2002
  • Number Of Employees:100+
  • Trade Capacity:Export Percentage:
  • Production Capacity:1
  • R&D Capacity:Less than 5 people
  • Quality Control:In House
  • No. of QC Staff:Less than 5 people
  • Registered Capital:Less than 1 Million USD
  • Total Annual Sales Volume:Less than 1 Million USD
  • Main Products:Etanercetp, Daclizumab, Rituximab And Trastuzumab,
  • Address:Libing Road, Shanghai, Shanghai, China
  • Main Markets:Asia,America,Europe,Middle East,Worldwide
  • Website:Visit website
Countries   China   India   Indonesia   Malaysia   Pakistan   Turkey   United Kingdom   United States   All Countries